ASPY, a company of the Atrys group, promotes health prevention in companies with a new genetic analysis service

ASPY, a company specialized in occupational risk prevention and occupational health and safety consultancy, belonging to the Atrys group, continues to grow with the aim of promoting preventive medicine services in the corporate environment. Under the commitment to support companies in improving the quality of life and well-being of their employees, it expands its services with a new line of preventive genetic analysis for workers. These studies allow the identification of possible risk factors and the early detection of diseases, facilitating medical follow-up and the adoption of healthy lifestyle habits.

The service, designed for companies that prioritize the promotion of the health and well-being of their employees, is backed by the extensive experience of the Atrys Genetics Laboratory, equipped with the latest sequencing techniques. This Unit has a complete catalog of genetic tests that it performs under the highest quality standards to advance its commitment to precision medicine and preventive medicine.

In this regard, Alfonso Alba, Vice President of Genetics at Atrys, states that “genetics has radically transformed the way we diagnose, treat and predict disease. Next-generation sequencing, together with computational analysis through AI, allows us to access detailed genetic information on our patients, which helps us to identify the underlying causes of many diseases with great precision and to determine personalized therapies.”

Thanks to this new service, ASPY makes available to working people, through their companies, an essential tool to detect risk factors inherent to their genetic inheritance, with the aim of identifying signs related to various pathologies, driving a proactive approach towards prevention and health care.

According to Pau Calvet, head of New Lines of ASPY Prevención, “we are committed to the integral health of working people. This new preventive health service, based on the detection of risk factors of genetic origin, offers companies an innovative tool for the care of their teams. A healthy and conscious work environment benefits both employees and the reduction of absenteeism and the healthy aging of the workforce. This service is an investment, not only in the future but also in the present of organizations, promoting a culture of care and proactive prevention”.

Preventive medicine within the reach of all employees: four types of studies through blood or saliva tests

The initiative is aimed at all those employees interested in maintaining a good state of health, with special focus on those workers who present clinical risk factors or habits that increase their vulnerability, employees already diagnosed with some pathology or people with a family history.

During the first months of activity, the new service will have four genetic studies; it will also offer two alternatives for taking samples, by blood extraction or saliva self-sampling, adapting to the preferences and needs of each company and employee. This first group of genetic tests includes:

Hereditary thrombophilia test: identifies genetic predisposition to alterations in blood coagulation.
General Cardiovascular Risk Test: evaluates genetic predisposition to heart disease.
Type 2 Diabetes Test: detects genetic factors associated with the development of this metabolic disease.
Nutrition and Wellness Test: analyzes how genetics can influence nutrient absorption and metabolism.

These analyses, whose results are governed by the strictest confidentiality standards, will provide employees with the information they need to take proactive measures to improve their lifestyle and state of health. In addition, the individual will be able to contact an ASPY doctor, who will help interpret the results and, if necessary, recommend a specialist doctor for diagnosis and clinical follow-up.

The service covers everything necessary to ensure an effective and personalized experience, including sampling material, laboratory analysis using advanced technology, secure downloading of results and personalized attention to resolve any doubts about the results.

Throughout the year, the company expects to continue expanding its portfolio of genetic services with new tests marketable to both companies and private users.